ArticleAntimicrobial agents and chemotherapy2014
Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Clinical Characteristics and Drug Resistance Mechanisms of Linezolid-Non-SusceptibleInfection and drug resistance · 2024Article
- Analysis of Antimicrobial Susceptibility in Bacterial Pathogens Associated with Urinary Tract Infections from Beijing Teaching Hospital in China, 2009-2017.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2023Article
- Mobile Oxazolidinone Resistance Genes in Gram-Positive and Gram-Negative Bacteria.Clinical microbiology reviews · 2021Article
- The Increasing Issue of Vancomycin-Resistant Enterococci and the Bacteriocin Solution.Probiotics and antimicrobial proteins · 2020Review
- Distribution and drug resistance of pathogenic bacteria in emergency patients.World journal of clinical cases · 2019Article
- Molecular Epidemiology and Mechanisms of 43 Low-Level Linezolid-ResistantAnnals of laboratory medicine · 2019Article
- Impact on Public Health of the Spread of High-Level Resistance to Gentamicin and Vancomycin in Enterococci.Frontiers in microbiology · 2018Review
- Five-Year Summary ofAntimicrobial agents and chemotherapy · 2017Article
- First Report of cfr-Carrying Plasmids in the Pandemic Sequence Type 22 Methicillin-Resistant Staphylococcus aureus Staphylococcal Cassette Chromosome mec Type IV Clone.Antimicrobial agents and chemotherapy · 2016Article
- Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).Antimicrobial agents and chemotherapy · 2016Article
- Livestock-Associated MRSA: The Impact on Humans.Antibiotics (Basel, Switzerland) · 2015Review
- Detection of a New cfr-Like Gene, cfr(B), in Enterococcus faecium Isolates Recovered from Human Specimens in the United States as Part of the SENTRY Antimicrobial Surveillance Program.Antimicrobial agents and chemotherapy · 2015Article
- In vitro activity of tedizolid against gram-positive bacteria in patients with skin and skin structure infections and hospital-acquired pneumonia: a Korean multicenter study.Annals of laboratory medicine · 2015Article
- Update on linezolid in vitro activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013.Antimicrobial agents and chemotherapy · 2015Article
- Clostridium difficile isolates with high linezolid MICs harbor the multiresistance gene cfr.Antimicrobial agents and chemotherapy · 2015Article
- Identification and characterization of linezolid-resistant cfr-positive Staphylococcus aureus USA300 isolates from a New York City medical center.Antimicrobial agents and chemotherapy · 2014Article
- Linezolid-resistant Staphylococcus aureus strain 1128105, the first known clinical isolate possessing the cfr multidrug resistance gene.Antimicrobial agents and chemotherapy · 2014Article
- What's New in the Treatment of Enterococcal Endocarditis?Current infectious disease reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study summarizes the linezolid susceptibility testing results for 7,429 Gram-positive pathogens from 60 U.S. sites collected during the 2012 sampling year for the LEADER Program. Linezolid showed potent activity when tested against 2,980 Staphylococcus aureus isolates, inhibiting all but 3 at ≤2 μg/ml. Similarly, linezolid showed coverage against 99.5% of enterococci, as well as for all streptococci tested. These results confirm a long record of linezolid activity against U.S. Gram-positive isolates since regulatory approval in 2000.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.